: Upgraded to Strong Buy by Truist Financial and BTIG Research .
Several biotechnology companies have recently earned ratings from analysts as of April 28, 2026. These ratings are often driven by positive clinical trial progress, strategic acquisitions, or analyst upgrades following strong performance. Latest Analyst "Strong Buy" Upgrades
Analysts have also highlighted smaller or more specialized innovators with high upside potential: Biotechnology - Yahoo Finance strong buy biotech stocks
: Rating increased to Strong Buy at Truist Financial.
These stocks have received specific "Strong Buy" ratings or upgrades from major financial institutions in late April 2026: : Upgraded to Strong Buy by Truist Financial
According to TipRanks and Yahoo Finance , the following large-cap biotech stocks currently hold a consensus rating: Gilead Sciences (GILD) Regeneron Pharmaceuticals (REGN) BioNTech (BNTX) Insmed Incorporated (INSM) IQVIA Holdings (IQV) Emerging Growth & Specialized Picks
: Raised to Strong Buy by HC Wainwright . Latest Analyst "Strong Buy" Upgrades Analysts have also
: Maintaining a Strong Buy outlook due to potential 2026 milestones . Top Biotech Stocks by Analyst Consensus